Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | ANPEP | P15144 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11660642 | 0.90 | HPGD (0.53) | KDM4EKMT2AL3MBTL1ALDH1A1HPGD | |
| SCHEMBL5696809 | 0.88 | KDM4E (0.61) | KDM4EKMT2AL3MBTL1ALDH1A1HPGD | |
| SCHEMBL30374739 | 0.86 | KDM4E (0.60) | KDM4EKMT2AL3MBTL1ALDH1A1HPGD | |
| SCHEMBL17880836 | 0.85 | KDM4E (0.73) | KDM4EKMT2AL3MBTL1ALDH1A1HPGD | |
| SCHEMBL14306608 | 0.85 | KDM4E (0.73) | KDM4EKMT2AL3MBTL1ALDH1A1HPGD | |
| SCHEMBL7300480 | 0.84 | KDM4E (0.57) | KDM4EKMT2AL3MBTL1ALDH1A1HPGD | |
| SCHEMBL283066 | 0.83 | ALDH1A1 (0.71) | KDM4EKMT2AALDH1A1HPGDGAA | |
| SCHEMBL7255889 | 0.81 | HPGD (0.54) | KDM4EKMT2AL3MBTL1ALDH1A1HPGD | |
| SCHEMBL7305558 | 0.81 | KDM4E (0.57) | KDM4EKMT2AL3MBTL1ALDH1A1HPGD | |
| SCHEMBL10959557 | 0.80 | ALDH1A1 (0.71) | KDM4EKMT2AL3MBTL1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355997-A1 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PRURITIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-12-14 | — | — | US | disclosed |
| US-20170355997-A1 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PRURITIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-12-14 | — | — | US | disclosed |
| US-9771592-B2 | Methods and compositions for treating or preventing pruritis | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771592-B2 | Methods and compositions for treating or preventing pruritis | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-09-26 | — | — | US | disclosed |
| US-20140303231-A1 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PRURITIS | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-10-09 | — | — | US | disclosed |
| US-20120073001-A1 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PRURITIS | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-03-22 | — | — | US | disclosed |
| WO-2010065085-A2 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PRURITIS | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-06-10 | — | — | WO | disclosed |
| US-20080027095-A1 | Use Of 3-Substituted-2-(Diphenylmethy)-1-Azabicyclo[2.2.2]Octanes For Treating Mrg-X1 Receptor Mediated Diseases | MERCK SHARP & DOHME CORP. | 2008-01-31 | — | — | US | disclosed |
| US-20080027095-A1 | Use Of 3-Substituted-2-(Diphenylmethy)-1-Azabicyclo[2.2.2]Octanes For Treating Mrg-X1 Receptor Mediated Diseases | MERCK SHARP & DOHME CORP. | 2008-01-31 | — | — | US | disclosed |
| US-20040077821-A1 | Flame retarding resin composition | CHANG CHUN PLASTICS CO., LTD. (TW) | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355997-A1 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PRURITIS | ITCH, CCL11, CPA3 | KDM4E 4703/4885KMT2A 4208/4885L3MBTL1 4800/4885 |
| US-20080027095-A1 | Use Of 3-Substituted-2-(Diphenylmethy)-1-Azabicyclo[2.2.2]Octanes For Treating Mrg-X1 Receptor Mediated Diseases | MRGPRX1, MRGPRX2, MRGPRX4 | KDM4E 1730/4885KMT2A 940/4885L3MBTL1 3366/4885 |
| US-20140303231-A1 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PRURITIS | ITCH, CCL11, CPA3 | KDM4E 4703/4885KMT2A 4208/4885L3MBTL1 4800/4885 |
| US-20120073001-A1 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PRURITIS | ITCH, CCL11, CPA3 | KDM4E 4703/4885KMT2A 4208/4885L3MBTL1 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.